Blair McNamara, MD
Cards
About
Research
Publications
2026
A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Ottum S, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S. A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932). Journal Of Clinical Oncology 2026, 44: 5575-5575. DOI: 10.1200/jco.2026.44.16_suppl.5575.Peer-Reviewed Original ResearchPlatinum-resistant ovarian cancerSacituzumab govitecanPhase II evaluationOvarian cancerOpen-label phase II studyActive metaboliteTreatment-emergent adverse eventsHigh-grade serous ovarian cancerMarkers of aggressive diseaseActive metabolite of irinotecanIntravenously day 1Phase II studyMedian Follow-UpECOG performance statusMetabolite of irinotecanFrequent grade 1Serous ovarian cancerAntibody-drug conjugatesMedian PFSMedian OSProgression-FreeSerous histologyStable diseaseAbdominal painStage III/IVA Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S. A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. Clinical Cancer Research 2026, of1-of10. PMID: 42132892, DOI: 10.1158/1078-0432.ccr-26-0144.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseOverall survivalSacituzumab govitecanH-scoreEndometrial cancerGrade 3 endometrioid tumorsMedian duration of responseMedian progression-free survivalClinical benefit rateRecurrent uterine cancerMedian Follow-UpTrop-2 expressionPhase II evaluationMean H scoreAdvanced/recurrent ECRecurrent ECSerous carcinomaPretreated populationTrop-2Primary endpointSecondary endpointsUterine cancerBenefit rateSafety profileSurvival benefit of interventions for malignant biliary obstruction in gynecologic oncology patients
Greenman M, Ferrucci C, Abozenah Y, Ettorre V, Ottum S, McNamara B, Papatla K, Kailasam A, Dottino P, Clark M, Ratner E, Santin A, Azodi M, Altwerger G. Survival benefit of interventions for malignant biliary obstruction in gynecologic oncology patients. Gynecologic Oncology 2026, 208: s288-s289. DOI: 10.1016/j.ygyno.2026.01.510.Peer-Reviewed Original ResearchUtility of vulvar cytology for vulvar cancer surveillance: A single institution retrospective analysis
Goreshnik A, Abozenah Y, McNamara B, Altwerger G. Utility of vulvar cytology for vulvar cancer surveillance: A single institution retrospective analysis. Gynecologic Oncology 2026, 208: s285-s286. DOI: 10.1016/j.ygyno.2026.01.505.Peer-Reviewed Original ResearchReal World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status
Dzienny A, Abozenah Y, Griffith J, Sohail S, Pan Y, Vlamis C, Yamartino K, Leclair J, Israel G, Greenman M, McNamara B, Azodi M, Ratner E, Santin A, Dottino P, Papatla K, Kailasam A, Hui P, Buza N, Altwerger G. Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status. Gynecologic Oncology Reports 2026, 65: 102084. PMID: 42095053, PMCID: PMC13139971, DOI: 10.1016/j.gore.2026.102084.Peer-Reviewed Original ResearchProgression-free survivalRecurrent endometrial cancerOptimal starting doseDose of lenvatinibHigh-grade tumorsP53 mutationsEndometrial cancerLenvatinib dosePlatinum resistanceP53 statusStarting doseAssociated with prolonged progression-free survivalPlatinum statusProlonged progression-free survivalOutcomes of pembrolizumabStandard starting doseEfficacy of pembrolizumabHigh-grade histologyIndividualized dosing strategiesMedian treatment durationBiomarkers of responseReal-world outcomesFewer dose reductionsReal-world cohortLow dose groupExperiences of OBGYN Administrative Chief Residents
Ransohoff A, Conageski C, Stonehocker J, Oberman E, McNamara B, Whetstone S. Experiences of OBGYN Administrative Chief Residents. Journal Of Surgical Education 2026, 83: 103935. PMID: 41916162, DOI: 10.1016/j.jsurg.2026.103935.Peer-Reviewed Original ResearchPatient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility
Levine A, Liu C, Harold J, McNamara B, Andikyan V. Patient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility. Cureus 2026, 18: e104373. PMID: 41913840, PMCID: PMC13033226, DOI: 10.7759/cureus.104373.Peer-Reviewed Original ResearchGynecologic cancer diagnosisMixed-methods studyFinancial toxicityCancer diagnosisInsurance coverageFinancial burdenLevel of insurance coverageLow financial burdenPatient-reported utilitiesResource handoutComprehensive insurance coverageIntervention perceptionsPatients' perceptionsMedical teamMixed-methodsGynecologic malignanciesEmployment disruptionOncological diagnosisFinancial resourcesInterventionStudy of feasibilityHandoutsPatient demographicsTreatment characteristicsParticipants
2025
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study
Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study. International Journal Of Gynecological Cancer 2025, 36: 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.Peer-Reviewed Original ResearchPlatinum-based chemotherapyPlatinum-based groupNon-platinum-based regimensOvarian carcinosarcomaCytoreductive surgeryOverall survivalRetrospective two-center cohort studyStage III to IV diseaseAdjuvant platinum-based chemotherapyMalignant mixed Mullerian tumorPlatinum-based chemotherapy regimensCox proportional hazards regression model analysisKaplan-Meier survival curvesMedian overall survivalMixed mullerian tumorsOptimal cytoreductive surgeryTwo-center cohort studyStandard chemotherapy regimenAdvanced-stage diseaseLog-rank testRetrospective chart reviewFirst-line approachYale-New Haven HospitalMulti-institutional studyNon-inferiority designPreclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleFocal Adhesion Kinase 1FulvestrantHumansMiceMice, SCIDOvarian NeoplasmsProtein Kinase InhibitorsReceptors, EstrogenXenograft Model Antitumor AssaysConceptsPatient-derived tumor xenograftTriple combinationFocal adhesion kinasePreclinical efficacyAromatase inhibitorsClinical evaluationEstrogen receptor (ER)-positiveAcquired resistance to chemotherapyOvarian cancer animal modelEstrogen receptor degrader fulvestrantPatients wild-typeVS-4718Cancer animal modelTumor growth inhibitionLimited treatment optionsResistance to chemotherapyP-ERK levelsFocal adhesion kinase inhibitorMedian survivalRare tumorOvarian carcinomaRecurrence rateTumor xenograftsTreatment optionsFulvestrantAdverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case
Abozenah Y, McNamara B, Greenman M, Daigle E, Mikhaiel J, DiCapua D, Kwan J, Azodi M, Altwerger G. Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case. Gynecologic Oncology Reports 2025, 61: 101950. PMID: 41169950, PMCID: PMC12570088, DOI: 10.1016/j.gore.2025.101950.Peer-Reviewed Original ResearchLife-threatening complicationsMyasthenia gravisImmune checkpoint inhibitor (ICI)-associated myocarditisComplication of ICI therapyPositive acetylcholine receptor antibodyHigh-dose steroidsTreated with carboplatinEndometrial cancer casesAcetylcholine receptor antibodiesDiagnosis of myocarditisElevated creatine kinaseCritical care managementICI therapyElevated troponinBilateral ptosisEndometrial adenocarcinomaReceptor antibodiesCardiac symptomsTherapeutic challengeMultidisciplinary managementRespiratory compromiseCardiac MRIAdverse eventsCancer casesDostarlimab
Academic Achievements & Community Involvement
Clinical Care
Overview
Blair C. McNamara, MD, specializes in treating patients with gynecologic cancers, including ovarian, uterine, cervical, and vulvar cancer. She provides comprehensive care for patients facing these conditions and offers individually tailored treatments that range from surgical interventions to chemotherapy. She has a passion for providing patients evidence-based treatments, including minimally invasive surgical techniques and cutting-edge targeted chemotherapies. She focuses on a “whole person” approach to cancer care and loves getting to know patients and their families while guiding them through the many choices that come with a new cancer diagnosis.
“I was drawn to gynecologic oncology very early on. It is a rare specialty in medicine where we get to offer both surgical and systemic (i.e. chemotherapy) treatments to our patients. This enables us to form long-lasting and deep bonds with our patients. that feel so rare in modern medicine more broadly.”
“We have a saying that once a patient receives a gyn cancer diagnosis, they are our patient forever! We work closely with their primary care physicians and other care team members to ensure that if they are living with cancer, or are free of disease, all aspects of their health are being tended to. I love getting to know my patients, their families, and I really feel that witnessing their strength and resilience while helping to care for them is one of the greatest privileges.”
As an assistant professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, Dr. McNamara conducts research aimed at improving surgical outcomes for patients. She is also investigating novel therapeutic strategies for patients with advanced or recurrent gynecologic malignancies.
Beyond taking excellent care of patients and their families, I have always wanted to have a career in academic medicine,” she explains. In all of medicine, but especially in cancer care, research has allowed us to fundamentally change the way we treat patients with gynecologic cancer. Even over the last 10 years, patients are living longer, getting cured of cancer more, and living with fewer side effects and toxicities from their treatments. Doing my part to push the field forward feels very important. Furthermore, teaching the next generation of physicians, OBGYNs, and gynecologic oncologists is so rewarding. We all have so much to learn from each other, and I love being at Yale, where there is such a strong legacy of education.”
Dr. McNamara received her medical degree from Yale School of Medicine, and completed her residency in obstetrics and gynecology at the University of California San Francisco. She then returned to Yale to complete a fellowship in gynecologic oncology.
Clinical Specialties
Board Certifications
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 2025
News & Links
Media
News
- January 06, 2026Source: Yale News
Office Hours: Getting to Know… Blair McNamara
- June 23, 2025
2025 OB/GYN Research and Graduation Day
- March 20, 2025
Smilow Cancer Hospital Gynecologic Oncology Expertise in Fairfield County
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.